Safety and efficacy of combined clozapine-lithium pharmacotherapy

International Journal of Neuropsychopharmacology

Volumn 7, Issue 1, 2004, Pages 59-63

  Bender, Stefan ^a,c   Linka, Thomas ^a   Wolstein, Jörg ^a   Gehendges, Susanne ^a   Paulus, Hermann Josef ^a   Schall, Ulrich ^b   Gastpar, Markus ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c Westfalische Klinik Marsberg   (Germany)

Author keywords

Adjunctive pharmacotherapy; Adverse events; Clozapine; Combined pharmacotherapy; Lithium

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CLOZAPINE; HALOPERIDOL; LITHIUM; LITHIUM CARBONATE; NEUROLEPTIC AGENT; PAROXETINE;

ACNE; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; DRUG EFFICACY; DRUG SAFETY; DYSKINESIA; EOSINOPHILIA; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; GOITER; GRAND MAL SEIZURE; HUMAN; HYPERSALIVATION; LEUKOPENIA; MALE; MUSCLE FATIGUE; MYOCLONUS; NEUROTOXICITY; PRIORITY JOURNAL; SEXUAL DYSFUNCTION; SWEATING; TACHYCARDIA; TREMOR; VERTIGO; VISUAL IMPAIRMENT; WEIGHT GAIN; XEROSTOMIA;

ADULT; AGED; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DRUG THERAPY, COMBINATION; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; LITHIUM; MALE; MIDDLE AGED; MYOCLONUS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 1942507484     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145703003870     Document Type: Article

References (26)

1. APA (1994). Diagnostic and Statistical Manual of Mental Disorders (4th edn). Washington, DC: American Psychiatric Association.
2. Angst J, Weis P, Grof P, Baastrup PC, Shou M (1970). Lithium prophylaxis in recurrent affective disorders. British Journal of Psychiatry 116, 604-614.
3. Bender S, Eap CB (1998). Very high cytochrome P4501A2 activity and nonresponse to clozapine. Archives of General Psychiatry 55, 1048-1050.
4. Bender S, Olbrich HM, Fischer W, Hornstein C, Schoene W, Falkai P, Haarmann C, Berger M, Gastpar M (2003). Antipsychotic efficacy of the antidepressant trimipramine: a double-blind comparison with the phenothiazine perazine. Pharmacopsychiatry 36, 61-69.
5. Bertillson L, Carrillo JA, Dahl ML, Llerena A, Alm C, Bondesson U, Lindstrom L, Rodriguez de la Rubia I, Ramos S, Benitez J (1994). Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. British Journal of Clinical Pharmacology 38, 471-473.
6. Biedermann J, Lerner Y, Belmaker RH (1979). Combination of lithium carbonate and haloperidol in schizoaffective disorder. Archives of General Psychiatry 36, 327-333.
7. Blake LM, Marks RC, Luchins DJ (1992). Reversible neurologic symptoms with clozapine and lithium. Journal of Clinical Psychopharmacology 12, 297-299.
8. Bryois C, Ferrero F (1993). Clinical observation of 11 patients under clozapine-lithium association. European Psychiatry 8, 213-218.
9. Carman JS, Bigelow LB, Wyatt RJ (1981). Lithium combined with neuroleptics in chronic schizophrenic and schizoaffective patients. Journal of Clinical Psychiatry 42, 124-128.
10. Cohen WJ, Cohen NH (1974). Lithium carbonate, haloperidol and irreversible brain damage. Journal of the American Medical Association 230, 1283-1287.
11. Devinsky O, Honigfeld G, Patin J (1991). Clozapine-related seizures. Neurology 41, 369-371.
12. Garcia G, Crismon ML, Dorson PG (1994). Seizures in two patients after the addition of lithium to a clozapine regimen. Journal of Clinical Psychopharmacology 14, 426-428.
13. Gastpar M (1989). Clinical originality and new biology of trimipramine. Drugs 38 (Suppl. 1), 43-48.
14. Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI (1999). Human cytochromes and some newer antidepressants: kinetics, metabolism, and drug interactions. Journal of Clinical Psychopharmacology 19 (Suppl. 1), 23S-35S.
15. Growe GA, Crayton JW, Klass DB, Evans H, Strizich M (1979). Lithium in chronic schizophrenia. American Journal of Psychiatry 136, 454-455.
16. Guy W (1976). ECDEU Assessment Manual for Psychopharmacology (rev.). Rockville, MD: U.S. National Institute of Health, Psychopharmacology Research Branch.
17. Kay SR, Opler LA, Fiszbein A (1992). Positive and Negative Syndrome Scale (PANSS) Manual. Toronto: Multi-Health Systems.
18. Koyama E, Chiba K, Tani M, Ishizaki T (1997). Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. Journal of Pharmacology and Experimental Therapeutics 281, 1199-1210.
19. Lemus CZ, Lieberman JA, Johns CA (1989). Myoclonus during treatment with clozapine and lithium: the role of serotonin. Hillside Journal of Clinical Psychiatry 11, 127-130.
20. Lenox RH, Husseini KM (1998). Lithium. In: Schatzberg AF, Nemeroff CB (Eds.), Textbook of Psychopharmacology (pp. 379-429). Washington, DC: American Psychiatric Press.
21. Lindström LH (1988). The effect of long-term treatment with clozapine in schizophrenia: a retrospective study in 96 patients treated with clozapine for up to 13 years. Acta Psychiatrica Scandinavica 77, 524-529.
22. Naber D, Holzbach R, Perro C, Hippius H (1992). Clinical management of clozapine patients in relation to efficacy and side effects. British Journal of Psychiatry 160 (Suppl. 17), 54-59.
23. Pope HG, Cole JO, Choras PT, Fulwiler CE (1986). Apparent neuroleptic malignant syndrome with clozapine and lithium. Journal of Nervous and Mental Disease 174, 493-495.
24. Small JG, Kellams JJ, Milstein V, Moore J (1975). A placebo-controlled study of lithium combined with neuroleptics in chronic schizophrenic patients. American Journal of Psychiatry 132, 1315-1317.
25. Tuunainen A, Wahlbeck K, Gilbody S (2002). Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials. Schizophrenia Research 56, 1-10.
26. Valevski A, Modai I, Lahav M, Weizman A (1993). Clozapine-lithium combined treatment and agranulocytosis. International Clinical Psychopharmacology 8, 63-65.